Remove Healthcare Remove Manufacturing Remove Networking Remove Prescription
article thumbnail

Addressing the Polypharmacy Problem

PM360

If one of those conditions is type 2 diabetes, that person may be taking seven prescription medications, 1 managing two or more additional chronic conditions, 2 and paying $13,000 per year on healthcare. senior adults (aged 65+) 7 taking five or more prescription medications. 3 They are also 2.6 In the U.S.,

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed. Medicines manufacturing is energy intensive.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

KFA-115 by Novartis for Melanoma: Likelihood of Approval

Pharmaceutical Technology

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. The company offers generic medicines and biosimilars through Sandoz. Novartis is headquartered in Basel, Switzerland.

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

One reason for this growth is an increasing demand for personalized healthcare technologies as patients look for advances in how healthcare is delivered following the pandemic. Unlike other formulary optimization solutions, Levrx delivers plan-specific and real-time prescription insights. billion in 2030 at a CAGR of 9.2%.

article thumbnail

J&J copay lawsuit against drug benefit firm gets green light

pharmaphorum

It is being supported by several patient advocacy groups, including the AIDS Institute, the National Oncology State Network, and the HIV + Hepatitis Policy Institute. The case is Johnson & Johnson Healthcare Systems v. Save On SP, LLC, 2:22-cv-02632, being heard in the US District Curt for the District of New Jersey.

Insurance 104
article thumbnail

KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval

Pharmaceutical Technology

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. The company offers generic medicines and biosimilars through Sandoz. Novartis is headquartered in Basel, Switzerland.

article thumbnail

Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval

Pharmaceutical Technology

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was also under development for the treatment of idiopathic/primary membranous nephropathy.